Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | CLPP | Q16740 | 2/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993341 | 0.87 | MEN1 (0.51) | LIMK1CLPPMEN1KMT2AMKNK1 | |
| SCHEMBL4986127 | 0.86 | LIMK1 (0.47) | TDP1LIMK1CLPPMKNK1PDE2A | |
| SCHEMBL4988843 | 0.86 | ALDH1A1 (0.47) | SMN1; SMN2LIMK1CLPPMEN1KMT2A | |
| SCHEMBL4992461 | 0.85 | LIMK1 (0.47) | LIMK1CLPPMEN1KMT2AMKNK1 | |
| SCHEMBL4982960 | 0.85 | LIMK1 (0.61) | TDP1LIMK1MEN1KMT2AMKNK1 | |
| SCHEMBL4985989 | 0.83 | KDM4E (0.50) | LIMK1CLPPMKNK1GAAKDM4E | |
| SCHEMBL4985030 | 0.83 | SIGMAR1 (0.50) | LIMK1CLPPMEN1KMT2AMKNK1 | |
| SCHEMBL4988786 | 0.83 | CLPP (0.51) | LIMK1CLPPPDE2A | |
| SCHEMBL4985486 | 0.82 | DRD2 (0.43) | TDP1LIMK1KMT2AMKNK1GAA | |
| SCHEMBL4986729 | 0.82 | ALDH1A1 (0.49) | SMN1; SMN2TDP1LIMK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | SMN1; SMN2 4369/4885TDP1 2440/4885LIMK1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.